Methods and products related to genome editing using the CRISPR/Cas9 system to introduce an A673T substitution into an APP gene, such as guide RNAs and recombinant proteins, are described for decreasing APP levels produced by a cell, and use for the treatment of Alzheimers disease and/or age-related cognitive decline in a cell from a subject in need thereof.